Preventing Diabetic Cardiovascular Disease

Schepens Eye Research Institute
posted on 03/04/2009

Atherosclerosis-related events such as myocardial infraction and stroke are two- to four- fold more prevalent in adults with diabetes as compared to those without diabetes. The invention focuses on the protein profilin-1 (pfn) as a mediator in diabetic vascular injury. Pfn levels are increased in the aortic endothelium and within atherosclerotic plaques and pfn knockout mice are protected against plaques onset. Circulating levels of profilin-1 could be used to predict the development of cardiovascular events and inhibition of profilin-1 accumulation would prevent the progression of atherosclerotic diseases.Diabetic vascular complications account for the vast majority of mortality occurring in diabetic patients. For at least 20 years, diabetes rates in North America have been increasing substantially affecting more than 20 million people in the United States alone. There is currently no biomarker for the diagnostic of atherosclerosis vascular diseases.

Innovation Details

File Number: SERI-147 

Other Information:

Ph.D Andrius Kazlauskas

Mary Chatterton, Director of Corporate Alliances.

IP Protection

License Online

This innovation currently is not available for online licensing. Please contact the case manager at Schepens Eye Research Institute for more information.

Request more info via email request more info

No people are currently associated with this innovation.

Download Technology Brief (PDF)

Followed By

Follow this innovation

No one is following this innovation.

Related Tags

Find more innovations

February 11, 2009

13,569 members 17,727 innovations 176 organizations


Martin Lehr, Osage University Partners

"iBridge is a great resource for entrepreneurs who are looking for technologies to license. Many premiere universities including Michigan, Columbia, MIT, Penn, and Harvard, participate in the iBridge program."  read more...